| First Author | Rulli SB | Year | 2024 |
| Journal | Mol Cell Endocrinol | Volume | 587 |
| Pages | 112214 | PubMed ID | 38537882 |
| Mgi Jnum | J:347717 | Mgi Id | MGI:7626141 |
| Doi | 10.1016/j.mce.2024.112214 | Citation | Rulli SB, et al. (2024) Elevated chorionic gonadotropic hormone in transgenic mice induces parthenogenetic activation and ovarian teratomas. Mol Cell Endocrinol 587:112214 |
| abstractText | Both male and female reproductive functions are impacted by altered gonadotrophin secretion and action, which may also influence the development of endocrine tumours. To ascertain if chronic hypersecretion of human chorionic gonadotropin (hCG) contributes to the development of gonadal tumours, double transgenic (TG) mice that overexpress hCGalpha- and beta-subunits were analysed. By the age of two months, ovarian tumours with characteristics of teratomas developed with 100% penetrance. Teratomas were also seen in wild-type ovaries orthotopically transplanted into TG mice, demonstrating an endocrine/paracrine mechanism for the hCG-induced ovarian tumorigenesis. Both in vitro and in vivo experiments showed oocyte parthenogenetic activation in TG females. In addition, ovaries showed reduced ovulatory gene expression, inhibited ERK1/2 phosphorylation, and impaired cumulus cell expansion. Hence, persistently high endocrine hCG activity causes parthenogenetic activation and development of ovarian teratomas, along with altered follicle development and impaired ERK1/2 signalling, offering a novel mechanism associated with the molecular pathogenesis of ovarian teratomas. |
